| ID | 10309 |
| Vaccine Name | MeMuRu-OKA |
| Disease Name | Measles, Mumps, Rubella, Varicella |
| Disease Classification | Exanthous |
| Virus Name | Morbillivirus, Mumps virus, Rubella virus, Varicella-zoster virus |
| Nucleic Acid Content | negative-sense, single-stranded RNA |
| Vaccine Type | Live-attenuated |
| Vaccine Status | Phase 2 |
| Manufacturer | GlaxoSmithKline |
| Year of Manufacturing | 2016 |
| Manufacturing Country | Canada |
| Age | 15 months - 6 years |
| Dosage | NA |
| Administration Route | Subcutaneous |
| Adjuvant | NA |
| Target Strain | Jeryl Lynn strain, Schwarz strain, RA 27/3 strain, OKA strain |
| Description | NA |
| Approving Organisation | NA |
| Collaborating Organisation | NA |
| Other Countries | NA |
| Trade Name | NA |
| PMID | NA |
| Clinical Trial ID | NCT00352898 |
| Reference Link | https://clinicaltrials.gov/ct2/show/NCT00352898 |
| Additional Links | https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-006065-14/DE
|